Repligen (NASDAQ:RGEN) Rating Increased to Hold at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

RGEN has been the topic of a number of other reports. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Finally, Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Trading Down 5.3 %

NASDAQ:RGEN opened at $142.43 on Wednesday. The company has a 50-day moving average price of $141.59 and a 200-day moving average price of $144.78. The stock has a market cap of $7.98 billion, a price-to-earnings ratio of -389.94, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the business posted $0.23 earnings per share. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities analysts predict that Repligen will post 1.45 EPS for the current year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after buying an additional 21,719 shares during the period. Champlain Investment Partners LLC increased its position in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC boosted its position in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.